Cracking result! Cash flowing in and EPS up very nicely (27.1%) to hopefully surpass 80 cents per share this year - might get some analyst upgrades after this result as I don't think even Jefferies with their recent $39.20 price target had these good results factored in. NPAT after tax up a very solid 28.7% which is great and I like the Profit before tax which was up 48.1% to nearly $22 Million in what is the weaker half by far for Clinuvel due to seasonality. The extra expenses for running a blockbuster phase 3 trial slated for completion this year are fine - have you ever heard of such a small/tiny Biotech running an absolute blockbuster phase 3 trial while consistently growing profits? It's looking great.
All IMO DYOR
CUV Price at posting:
$12.25 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)